natgillin/translations-raw huggingface dataset:
- Rash, red skin with blisters on the lips, eyes, skin or mouth, peeling skin, fever, raised red or purple skin patches, itching, burning sensation, pustular eruption (signs of skin problems). 
- osip, crvenilo kože s mjehurićima na usnama, očima, koži ili u ustima, ljuštenje kože, vrućica, izdignuti crveni ili ljubičasti plikovi na koži, svrbež, osjećaj žarenja, pojava gnojnih mjehurića
One open label, multicentre, phase II clinical trial (study B2225) was conducted testing imatinib in diverse populations of patients suffering from life-threatening diseases associated with Abl, Kit or PDGFR protein tyrosine kinases. 
Provedeno je jedno otvoreno, multicentrično kliničko ispitivanje faze II (studija B2225) za ispitivanje imatiniba u raznim populacijama bolesnika koji pate od bolesti opasnih po život povezanih s Abl, Kit ili PDGFR protein tirozin kinazama.
- If any of these affect you severely, tell your doctor. 
- Ako se bilo što od navedenog kod Vas javi u teškom obliku, obavijestite svog liječnika.
Imatinib may increase plasma concentration of other CYP3A4 metabolised drugs (e.g. triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, i.e. statins, etc.). 
CYP3A4 (npr. triazolo-benzodiazepini, dihidropiridinski blokatori kalcijevih kanala, određeni inhibitori HMG-CoA reduktaze odnosno statini, itd.).
Relapsed/refractory Ph+ ALL: When imatinib was used as single agent in patients with relapsed/refractory Ph+ ALL, it resulted, in the 53 out of 411 patients evaluable for response, in a haematological response rate of 30% (9% complete) and a major cytogenetic response rate of 23%. 
Recidivirajući ili refraktorni Ph+ ALL: kada je imatinib samostalno korišten u bolesnika s recidivirajućim ili refraktornim Ph+ ALL-om, rezultirao je s odgovorom u 53 od 411 procijenjenih bolesnika, sa stopom hematološkog odgovora od 30% (9% potpuni) i stopom većeg citogenetskog odgovora od 23%.
In GIST patients (study B2222), 6.8% of grade 3 or 4 
U bolesnika s GIST-om (studija B2222), zapaženo je 6,8% ALT
Pack sizes: The capsules are supplied in aluminium blister packs of 24, 48, 60, 96, 120 or 180 capsules. 
Veličine pakiranja: Kapsule se isporučuju u aluminijskim blisterima od 24, 48, 60, 96, 120 ili 180 kapsula.
G-CSF = granulocyte colony stimulating factor, VP-16 = etoposide, MTX = methotrexate, IV = intravenous, SC = subcutaneous, IT = intrathecal, PO = oral, IM = intramuscular, ARA-C = cytarabine, CPM = cyclophosphamide, VCR = vincristine, DEX = dexamethasone, DAUN = daunorubicin, 6-MP = 6-mercaptopurine, E.Coli L-ASP = L-asparaginase, PEG-ASP = PEG asparaginase, MESNA= 2-mercaptoethane sulfonate sodium, iii= or until MTX level is < 0.1 µM, q6h = every 6 hours, Gy= Gray 
= ciklofosfamid, VCR = vinkristin, DEX = deksametazon, DAUN = daunorubicin, 6-MP = 6merkaptopurin, E.Coli L-ASP = L-asparaginaza, PEG-ASP = PEG asparaginaza, MESNA= natrijev 2merkaptoetan sulfonat, iii= ili dok vrijednost MTX-a ne bude <0,1 µm, Gy= Gray
How long to take Imatinib Actavis 
Koliko dugo uzimati Imatinib Actavis
Acute febrile neutrophilic dermatosis (Sweet's syndrome), nail discolouration, angioneurotic oedema, rash vesicular, erythema multiforme, leucocytoclastic vasculitis, Stevens-Johnson syndrome, acute generalised exanthematous pustulosis (AGEP) 
Akutna febrilna neutrofilna dermatoza (Sweetov sindrom), promjena boje nokta, angioedem, vezikularni osip, multiformni eritem, leukocitoklastični vaskulitis, Stevens-Johnsonov sindrom, akutna generalizirana egzantematozna pustuloza (AGEP)
Pack sizes: The capsules are supplied in aluminium blister packs of 30 or 90 capsules. 
Veličine pakiranja: Kapsule se isporučuju u aluminijskim blisterima od 30 ili 90 kapsula.
Study 0102 38-month data Myeloid blast crisis (n=260) % of patients (CI95%) 
(n=260) % bolesnika (CI95%)
Imatinib Actavis inhibits the growth of these cells. 
Imatinib Actavis inhibira rast ovih stanica.
4 Flushing was most common in GIST patients and bleeding (haematoma, haemorrhage) was most common in patients with GIST and with transformed CML (CML-AP and CML-BC). 
4 Crvenilo uz osjećaj vrućine je bilo najčešće u GIST bolesnika, a krvarenje (hematomi, hemoragija) je bilo najčešće u bolesnika s GIST-om i s transformiranim KML-om (KML
Posology for CML in paediatric patients Dosing for children should be on the basis of body surface area (mg/m2). 
U djece se doziranje treba temeljiti na veličini površine tijela (mg/m2).
The median time to progression in the overall population of 411 patients with relapsed/refractory Ph+ ALL ranged from 2.6 to 3.1 months, and median overall survival in the 401 evaluable patients ranged from 4.9 to 9 months. 
Medijan vremena do progresije u ukupnoj populaciji od 411 bolesnika s recidivirajućim ili refraktornim Ph+ ALL-om kretao se od 2,6 do 3,1
12 Gy in 8 fractions for all patients that are CNS1 and CNS2 at diagnosis 18 Gy in 10 fractions for patients that are CNS3 at diagnosis VCR (1.5 mg/m2/day, IV): days 1, 29 
18 Gy u 10 frakcija za bolesnike koji imaju CNS3 u trenutku dijagnoze VCR (1,5 mg/m2/dan, i.v.): dani 1, 29
In the study in patients with unresectable and/or metastatic GIST, 7 (5%) patients experienced CTC grade 3/4 GI bleeds (3 patients), intra-tumoural bleeds (3 patients) or both (1 patient). 
bolesnika nastupilo je GI krvarenje CTC stupnja 3/4 (3 bolesnika), intratumorsko krvarenje (3 bolesnika) ili oboje (1 bolesnik).
- Muscle cramps or joint, muscle or bone pain, during imatinib treatment or after you have stopped taking imatinib. 
- grčevi u mišićima ili bol u zglobovima, mišićima ili kostima, tijekom liječenja imatinibom ili nakon prekida uzimanja imatiniba..
Imatinib Actavis is indicated for - the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery. 
- liječenje odraslih bolesnika s inoperabilnim dermatofibrosarkomom protuberans (DFSP) i odraslih bolesnika s rekurentnim i/ili metastazirajućim DFSP-om koji nisu podobni za kirurški zahvat.
If any of these affect you severely, tell your doctor. 
Ako se bilo što od navedenog kod Vas javi u teškom obliku, obavijestite svog liječnika.
Palpitations, tachycardia, cardiac failure congestive3, pulmonary oedema 
Palpitacije, tahikardija, kongestivno zatajenje srca3, plućni edem
- Difficulty in sleeping (insomnia). 
- omaglica ili slabost. - otežano spavanje (nesanica).
If cytopenia persists for 4 weeks and is still unrelated to leukaemia, stop imatinib until ANC ≥ 1 x 109/L and platelets ≥ 20 x 109/L, then resume treatment at 200 mg/m2. 
Ako citopenija ustraje 4 tjedna i još uvijek nije povezana s leukemijom, prekinuti primjenu imatiniba sve dok ABN ne bude ≥1 x 109/l i trombociti ≥20 x 109/l, nakon toga nastaviti liječenje u dozi od 200 mg/m2.
If cytopenia persists for 4 weeks and is still unrelated to leukaemia, stop imatinib until ANC ≥ 1 x 109/L and platelets ≥ 20 x 109/L, then resume treatment at 300 mg. 
Ako citopenija ustraje 4 tjedna i još uvijek nije povezana s leukemijom, prekinuti primjenu imatiniba sve dok ABN ne bude ≥1 x 109/l i trombociti ≥20 x 109/l, nakon toga nastaviti liječenje u dozi od 300 mg.
Methotrexate (20 mg/m2/week, PO): days 8, 15, 22 VP-16 (100 mg/m2, IV): days 29-33 
Metotreksat (20 mg/m2/tjedan, p.o.): dani 8, 15, 22 VP-16 (100 mg/m2, i.v.): dani 29-33
Clinical studies in DFSP One phase II, open label, multicentre clinical trial (study B2225) was conducted including 12 patients with DFSP treated with imatinib 800 mg daily. 
Provedeno je jedno otvoreno, multicentrično kliničko ispitivanje faze II (studija B2225) koje je uključivalo 12 bolesnika s DFSP-om liječenih imatinibom 800 mg na dan.
Skin and subcutaneous tissue disorders 
Poremećaji kože i potkožnog tkiva Vrlo često
Thyroid stimulating hormone (TSH) levels should be closely monitored in such patients. 
U takvih bolesnika trebaju se pažljivo pratiti razine tireotropina (TSH).
Gynaecomastia, erectile dysfunction, menorrhagia, menstruation irregular, sexual dysfunction, nipple pain, breast enlargement, scrotal oedema 
Ginekomastija, erektilna disfunkcija, menoragija, nepravilne mjesečnice, poremećaj seksualne funkcije, bol u bradavicama, povećanje dojki, edem skrotuma
Treatment schedule: On the basis of the existing data, imatinib has been shown to be effective and safe when administered at 600 mg/day in combination with chemotherapy in the induction phase, the consolidation and maintenance phases of chemotherapy (see section 5.1) for adult patients with newly diagnosed Ph+ ALL. 
600 mg/ dan u kombinaciji s kemoterapijom u indukcijskoj fazi te u konsolidacijskoj fazi i fazi održavanja kemoterapije (vidjeti dio 5.1) u odraslih bolesnika s novodijagnosticiranim Ph+ ALL-om.
Liver dysfunction 
Poremećaj funkcije jetre
Doses of 400 mg or 600 mg should be administered once daily, whereas a daily dose of 800 mg should be administered as 400 mg twice a day, in the morning and in the evening. 
Doze od 400 mg ili 600 mg trebaju se primijeniti jednom na dan, dok se dnevna doza od 800 mg treba primijeniti kao 400 mg dvaput na dan,
8 Some fatal cases of hepatic failure and of hepatic necrosis have been reported. 
8 Zabilježeno je nekoliko smrtnih slučajeva zbog zatajenja jetre i nekroze jetre.
MESNA (360 mg/m2/dose q3h, x 8 doses/day, IV): days 1-5 G-CSF (5 μg/kg, SC): days 6-15 or until ANC > 1500 post nadir IT Methotrexate (age-adjusted): day 1 ONLY Triple IT therapy (age-adjusted): day 8, 15 
MESNA (360 mg/m2/doza svaka 3 sata x 8 doza/dan, i.v.): dani 1-5 G-CSF (5 μg/kg, s.c.): dani 6-15 ili do porasta ANC >1500 nakon najniže izmjerene vrijednosti i.t. metotreksat (prilagođeno dobi): SAMO dan 1 Trostruka i.t. terapija (prilagođena dobi): dan 8, 15
Paediatric patients: A total of 26 paediatric patients of age < 18 years with either chronic phase CML (n=11) or CML in blast crisis or Ph+ acute leukaemias (n=15) were enrolled in a dose-escalation phase I trial. 
<18 godina bilo s kroničnom fazom KML-a (n=11), bilo s KML-om u blastičnoj krizi ili Ph+ akutnim leukemijama (n=15).
The age of these patients ranged from 3 months to 4 years and imatinib was given at dose 50 mg daily or doses ranging from 92.5 to 340 mg/m2 daily. 
Dob tih bolesnika bila je u rasponu od 3 mjeseca do 4 godine, a imatinib se primjenjivao u dozi od 50 mg na dan ili dozama u rasponu od 92,5 do 340 mg/m2 na dan.
Herpes zoster, herpes simplex, nasopharyngitis, pneumonia1, sinusitis, cellulitis, upper respiratory tract infection, influenza, urinary tract infection, gastroenteritis, sepsis 
Herpes zoster, herpes simplex, nazofaringitis, upala pluća1, sinusitis, celulitis, infekcija gornjih dišnih puteva, gripa, infekcija mokraćnog sustava,
- If you are being treated for CML: 
- Ako se liječite zbog KML-a:
- Pale skin, feeling tired and breathlessness and having dark urine (signs of low levels of red blood cells). 
- blijeda koža, umor i gubitak daha te tamno obojena mokraća (znakovi snižene razine crvenih krvnih stanica).
Excipients(s) 
Pomoćna(e) tvar(i)
Triple IT therapy (age-adjusted): days 1 and 22 
Trostruka i.t. terapija (prilagođena dobi): dani 1 i 22
- Severe abdominal pain, blood in your vomit, stools or urine, black stools (signs of gastrointestinal disorders). 
- teška bol u trbuhu, krv u sadržaju povraćanja, stolici ili mokraći, crne stolice (znakovi probavnih problema).
Newly diagnosed Ph+ ALL: In a controlled study (ADE10) of imatinib versus chemotherapy induction in 55 newly diagnosed patients aged 55 years and over, imatinib used as single agent induced a significantly higher rate of complete haematological response than chemotherapy (96.3% vs. 50%; p=0.0001). 
Novodijagnosticirani Ph+ ALL: u kontroliranom ispitivanju (ADE10) imatiniba u odnosu na kemoterapiju u 55 novodijagnosticiranih bolesnika u dobi od 55 godina i više, imatinib korišten samostalno izazvao je značajno višu stopu potpunog hematološkog odgovora nego kemoterapija (96,3% u odnosu na 50%; p=0,0001).
Muscle spasm and cramps, musculoskeletal pain including myalgia9, arthralgia, bone pain10 
Spazam mišića i grčevi, mišićno-koštana bol uključujući mialgiju, artralgiju,
Caution should be used when taking imatinib with protease inhibitors, azole antifungals, certain macrolides (see section 4.5), CYP3A4 substrates with a narrow therapeutic window (e.g. cyclosporine, pimozide, tacrolimus, sirolimus, ergotamine, diergotamine, fentanyl, alfentanil, terfenadine, bortezomib, docetaxel, quinidine) or warfarin and other coumarin derivatives (see section 4.5). 
Potreban je oprez kada se imatinib uzima s inhibitorima proteaze, azolnim antimikoticima, određenim makrolidima (vidjeti dio 4.5), CYP3A4 supstratima s uskim terapijskim prozorom (npr. ciklosporin, pimozid, takrolimus, sirolimus, ergotamin, diergotamin, fentanil, alfentanil, terfenadin, bortezomib, docetaksel, kinidin) ili varfarinom i drugim derivatima kumarina (vidjeti dio 4.5).
Substances that are inducers of CYP3A4 activity e.g. dexamethasone, phenytoin, carbamazepine, rifampicin, phenobarbital, fosphenytoin, primidone or Hypericum perforatum, also known as St. John's Wort) may significantly reduce exposure to imatinib, potentially increasing the risk of therapeutic failure. 
Tvari koje induciraju djelovanje CYP3A4 (npr. deksametazon, fenitoin, karbamazepin, rifampicin, fenobarbital, fosfenitoin, primidon ili Hypericum perforatum, poznat također kao gospina trava) mogu značajno smanjiti izloženost imatinibu, čime se potencijalno povećava rizik od neuspjeha terapije.
ARA-C (3 g/m2/dose q 12 h x 4, IV): days 2 and 3 G-CSF (5 μg/kg, SC): days 4-13 or until ANC > 1500 post nadir 
ARA-C (3 g/m2/doza svakih 12 sati x 4, i.v.): dani 2 i 3 G-CSF (5 μg/kg, s.c.): dani 4-13 ili do porasta ANC >1500 nakon najniže izmjerene vrijednosti
Methotrexate (20 mg/m2/week, PO): days 8, 15, 22, 29, 36, 43, 50 
Metotreksat (20 mg/m2/tjedan, p.o.): dani 8, 15, 22, 29, 36, 43, 50
- Severely decreased urine output, feeling thirsty (signs of kidney problems). 
- jako smanjeno mokrenje, žeđ (znakovi bubrežnih problema).
5 Pleural effusion was reported more commonly in patients with GIST and in patients with transformed CML (CML-AP and CML-BC) than in patients with chronic CML. 
Pleuralni izljev je češće zabilježen u bolesnika s GIST-om i u bolesnika s transformiranim KML-om (KML-ubrzana faza i KML-blastična kriza), nego u bolesnika s kroničnim KML-om.
Ifosfamide (1.8 g/m2/day, IV): days 1-5 
Ifosfamid (1,8 g/m2/dan, i.v.): dani 1-5
Thrombotic microangiopathy 
Trombotična mikroangiopatija
Methotrexate (20 mg/m2/week, PO): days 1, 8, 15, 22, 29, 36, 43, 50 
Metotreksat (20 mg/m2/tjedan, p.o.): dani 1, 8, 15, 22, 29, 36, 43, 50
In newly diagnosed chronic phase CML grade 4 neutropenia (ANC < 0.5 x 109/L) and thrombocytopenia (platelet count < 10 x 109/L) were observed in 3.6% and < 1% of patients, respectively. 
<0,5 x 109/l) i trombocitopenija (broj trombocita <10 x 109/l) zapažene su u 3,6% odnosno <1%
Therapy should be initiated by a physician experienced in the treatment of patients with haematological malignancies and malignant sarcomas, as appropriate. 
4.2 Doziranje i način primjene Terapiju treba započeti liječnik s iskustvom u liječenju bolesnika s hematološkim zloćudnim bolestima, odnosno malignim sarkomima.
11th Ion Mihalache Ave, The 1st district, RO-011171 Bucharest 
RO-011171 Bucharest Rumunjska
Therefore, caution is recommended when administering imatinib with CYP3A4 substrates with a narrow therapeutic window (e.g. cyclosporine, pimozide, tacrolimus, sirolimus, ergotamine, diergotamine, fentanyl, alfentanil, terfenadine, bortezomib, docetaxel and quinidine). 
Zbog toga se preporučuje oprezno postupati kada se imatinib primjenjuje s CYP3A4 supstratima s uskim terapijskim prozorom (npr. ciklosporin, pimozid, takrolimus, sirolimus, ergotamin, diergotamin, fentanil, alfentanil, terfenadin, bortezomib,
Because of known increased risks of bleeding in conjunction with the use of imatinib (e.g. haemorrhage), patients who require anticoagulation should receive low-molecular-weight or standard heparin instead of coumarin derivatives such as warfarin. 
bolesnici kojima je potrebna antikoagulacija trebaju primati heparin niske molekularne težine ili standardni heparin, umjesto kumarinskih derivata kao što je varfarin.
Pack sizes: The tablets are supplied in aluminium blister packs of 10, 30, 60 or 90 film-coated tablets. 
Veličine pakiranja: Tablete se isporučuju u aluminijskim blisterima od 10, 30, 60, ili 90 filmom obloženih tableta.
- The other ingredients are: Capsule content: cellulose microcrystalline, copovidone, crospovidone, sodium stearyl fumarate, silica (colloidal hydrophobe and colloidal anhydrous). 
Drugi sastojci su: Sadržaj kapsule: mikrokristalična celuloza, kopovidon, krospovidon, natrijev stearilfumarat, silicijev dioksid (koloidni hidrofobni i koloidni bezvodni).
Active substances that may increase imatinib plasma concentrations: 
Djelatne tvari koje mogu povećati koncentracije imatiniba u plazmi:
Your doctor will tell you exactly how many tablets of Imatinib Actavis to take. 
Liječnik će Vam reći točno koliko tableta Imatinib Actavisa trebate uzeti.
You may feel dizzy or drowsy or get blurred vision while taking this medicine. 
Tijekom uzimanja ovog lijeka možete osjetiti omaglicu, omamljenost ili imati zamagljen vid.
6-MP (75 mg/m2/day, PO): days 1-56 
6-MP (75 mg/m2/dan, p.o.): dani 1-56
- Painful and/or blistering skin lesions. 
- lezije (oštećenja) kože koje su bolne i/ili s mjehurićima.
15 mg intrathecal, days 1, 8, 15, 22; Ara-C 40 mg intrathecal, days 1, 8, 15, 22; methylprednisolone 40 mg intrathecal, days 1, 8, 15, 22 
MTX 15 mg intratekalno, dani 1, 8, 15, 22; Ara-C 40 mg intratekalno, dani 1, 8, 15, 22; metilprednizolon 40 mg intratekalno, dani 1, 8, 15, 22
Return to chronic phase (RTC) Major cytogenetic response2 
Vraćanje na kroničnu fazu (RTC)
VCR 1.3 g/m2 i.v., day 1; prednisolone 60 mg/m2 oral, days 1-5 
VCR 1,3 g/m2 i.v., dan 1; prednizolon 60 mg/m2 peroralno, dani 1-5
Imatinib Actavis 50 mg hard capsules Al/PVC/Aclar blister. 
Imatinib Actavis 50 mg tvrde kapsule Al/PVC/Aclar blister.
The age of these patients ranged from newborn to 14 years and imatinib was given at dose 50 mg daily or doses ranging from 400 to 520 mg/m2 daily. 
Dob tih bolesnika bila je u rasponu od novorođenčadi do 14 godina, a imatinib se primjenjivao u dozi od 50 mg na dan ili u dozama u rasponu od 400 do 520 mg/m2 na dan.
The doctor will tell you how many tablets of Imatinib Actavis to give to your child. 
Liječnik će Vam reći koliko tableta Imatinib Actavisa trebate dati djetetu.
- The other ingredients are cellulose microcrystalline, copovidone, crospovidone, sodium stearyl fumarate, silica (colloidal hydrophobe and colloidal anhydrous), polyvinyl alcohol partly hydrolysed, talc, yellow iron oxide (E172), titanium dioxide (E171), red iron oxide (E172), lecithin (soya) (E322), xanthan gum (E415). 
Drugi sastojci su: mikrokristalična celuloza, kopovidon, krospovidon, natrijev stearilfumarat, silicijev dioksid (koloidni hidrofobni i koloidni bezvodni), poli(vinilni alkohol) djelomično hidroliziran, talk, žuti željezov oksid (E172), titanijev dioksid (E171), crveni željezov oksid (E172), sojin lecitin (E322), ksantanska guma (E415).
All 65 FIP1L1-PDGFRα fusion kinase positive patients achieved a CHR sustained for months (range from 1+ to 44+ months censored at the time of the reporting). 
Svih 65 bolesnika s pozitivnom FIP1L1-PDGFRα fuzijskom kinazom postiglo je CHR održan mjesecima
Neutropenia, thrombocytopenia, anaemia 
Neutropenija, trombocitopenija, anemija
The doctor will tell you how many capsules of Imatinib Actavis to give to your child. 
Liječnik će Vam reći koliko kapsula Imatinib Actavisa trebate dati djetetu.
Nausea, diarrhoea, vomiting, dyspepsia, abdominal pain6 
Mučnina, proljev, povraćanje, dispepsija, bol u trbuhu6
The European Medicines Agency has waived the obligation to submit the results of studies with imatinib in all subsets of the paediatric population in Philadelphia chromosome (bcr-abl translocation)positive chronic myeloid leukaemia (see section 4.2 for information on paediatric use). 
Europska Agencija za lijekove je izuzela obvezu podnošenja rezultata ispitivanja lijeka imatiniba u svim podskupinama pedijatrijske populacije s kroničnom mijeloičnom leukemijom s pozitivnim
The required number of tablets should be placed in the appropriate volume of beverage (approximately 50 ml for a 100 mg tablet, and 200 ml for a 400 mg tablet) and stirred with a spoon. 
(oko 50 ml za tabletu od 100 mg i 200 ml za tabletu od 400 mg) i promiješati žlicom.
Imatinib Actavis 100 mg hard capsules Al/PVC/Aclar blister. 
Imatinib Actavis 100 mg tvrde kapsule Al/PVC/Aclar blister.
The dose is 800 mg per day (2 tablets), to be taken as one tablet in the morning and a second tablet in the evening. 
Doza je 800 mg na dan (2 tablete), koje se uzimaju kao jedna tableta ujutro i druga tableta navečer.
Your doctor will tell you exactly how many capsules of Imatinib Actavis to take. 
Liječnik će Vam reći točno koliko kapsula Imatinib Actavisa trebate uzeti.
days 2, 3, 16, and 17 
6 doza) iii: dani 2, 3, 16 i 17
Days 2, 3, 16, and 17 
6 doza)iii: Dani 2, 3, 16 i 17
CPM (300 mg/m2, IV): days 29-33 
CPM (300 mg/m2, i.v.): dani 29-33
Active substances that may decrease imatinib plasma concentrations: 
Djelatne tvari koje mogu smanjiti koncentracije imatiniba u plazmi:
MESNA (150 mg/m2/day, IV): days 22-26 
MESNA (150 mg/m2/dan, i.v.): dani 22-26
If any of these apply to you, tell your doctor before taking Imatinib Actavis. 
Ako se bilo što od navedenog odnosi na Vas, obavijestite svog liječnika prije uzimanja Imatinib
The tablets are supplied in aluminium blister packs of 10, 20, 30, 60, 90, 120 or 180 film-coated tablets. 
Veličine pakiranja: Tablete se isporučuju u aluminijskim blisterima od 10, 20, 30, 60, 90, 120 ili 180 filmom obloženih tableta
Nervous system disorders 
Poremećaji živčanog sustava Vrlo često
Imatinib Actavis 100 mg film-coated tablets Each film-coated tablet contains 100 mg imatinib (as mesilate). 
Imatinib Actavis 100 mg filmom obložene tablete Svaka filmom obložena tableta sadrži 100 mg imatiniba (u obliku imatinibmesilata).
DEX (6 mg/m2/day, PO): days 1-7 and 15-21 
DEX (6 mg/m2/dan, p.o.): dani 1-7 i 15-21
The age of these patients ranged from 2 to 16 years and imatinib was given at dose 300 mg/m2 daily or doses ranging from 200 to 400 mg daily. 
Dob tih bolesnika bila je u rasponu od 2 do 16 godina, a imatinib se primjenjivao u dozi od 300 mg/m2 na dan ili u dozama u rasponu od 200 do 400 mg na dan.
Imatinib was teratogenic in rats when administered during organogenesis at doses ≥ 100 mg/kg, 
Imatinib je bio teratogen u štakora kada je primjenjivan tijekom organogeneze u dozama ≥100 mg/kg, koje su približno jednake maksimalnoj kliničkoj dozi od 800 mg/dan, temeljeno na veličini površine tijela.
VP-16 (100 mg/m2/day, IV): days 1-5 
VP-16 (100 mg/m2/dan, i.v.): dani 1-5
Imatinib is a small molecule protein-tyrosine kinase inhibitor that potently inhibits the activity of the Bcr-Abl tyrosine kinase (TK), as well as several receptor TKs: Kit, the receptor for stem cell factor (SCF) coded for by the c-Kit proto-oncogene, the discoidin domain receptors (DDR1 and DDR2), the colony stimulating factor receptor (CSF-1R) and the platelet-derived growth factor receptors alpha and beta (PDGFR-alpha and PDGFR-beta). 
stem cell factor) kodiran c-Kit protoonkogenom, receptore za diskoidinsku domenu (DDR1 i DDR2, engl. discoidin domain receptors), receptor za faktor stimulacije kolonija (CSF-1R, engl. colony stimulating factor receptor) te alfa i beta receptore za faktor rasta koji potječe od trombocita (PDGFR
EU/1/13/825/003 24 capsules EU/1/13/825/004 48 capsules EU/1/13/825/019 60 capsules EU/1/13/825/005 96 capsules EU/1/13/825/006 120 capsules EU/1/13/825/007 180 capsules 
EU/1/13/825/003 24 kapsule EU/1/13/825/004 48 kapsula EU/1/13/825/019 60 kapsula EU/1/13/825/005 96 kapsula EU/1/13/825/006 120 kapsula EU/1/13/825/007 180 kapsula
Imatinib Actavis 400 mg hard capsules Al/PVC-PVDC blister. 
Imatinib Actavis 400 mg tvrde kapsule Al/PVC-PVDC blister.
Pack sizes: The capsules are supplied in aluminium blister packs of 10, 30, 60, or 90 capsules. 
Veličine pakiranja: Kapsule se isporučuju u aluminijskim blisterima od 10, 30, 60 ili 90 kapsula.